Inhibition of ADAM9 Expression Induces Epithelial Phenotypic Alterations and Sensitizes Human Prostate Cancer Cells to Radiation and Chemotherapy

Overview

Journal Prostate

Date 2010 Jul 31

PMID 20672324

Citations 29

Authors

Sajni Josson

Cynthia S Anderson

Shian-Ying Sung

Peter A S Johnstone

Hiroyuki Kubo

Chia-Ling Hsieh

Rebecca Arnold

Murali Gururajan

Clayton Yates

Leland W K Chung

Affiliations

Soon will be listed here.

Abstract

Introduction: Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy.

Materials And Methods: ADAM9 was either transiently or stably knocked down in C4-2 prostate cancer cells. The sensitivity of ADAM9 knockdown cells toward radiation and chemotherapeutic agents were determined. Additionally, the effects of ADAM9 knockdown on prostate cancer cell morphology, biochemical and functional alterations were accessed.

Results: Both transient and stable knockdown of ADAM9 resulted in increased apoptosis and increased sensitivity to radiation. ADAM9 knockdown also increased prostate cancer sensitivity to several chemotherapeutic drugs. ADAM9 knockdown resulted in increased E-cadherin and altered integrin expression and underwent phenotypic epithelial transition. These were reflected by the morphological, biochemical, and functional alterations in the ADAM9 knockdown cells.

Conclusions: ADAM9 plays a crucial role in prostate cancer progression and therapeutic resistance in part by altering E-cadherin and integrin expression. ADAM9 is an important target for the consideration of treating prostate cancer patients who developed therapeutic resistance and disease relapse.

Citing Articles

Genetic variants of ADAM9 as potential predictors for biochemical recurrence in prostate cancer patients after receiving a radical prostatectomy.

Lin Y, Wen Y, Lin C, Hsiao C, Ho K, Huang H Int J Med Sci. 2024; 21(15):2934-2942.

PMID: 39628685 PMC: 11610326. DOI: 10.7150/ijms.103179.

The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer.

Le T, Hsieh C, Lin I, Chu C, Do A, Chen S Am J Cancer Res. 2022; 12(1):176-197.

PMID: 35141012 PMC: 8822277.

The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth.

Manoukian P, Bijlsma M, van Laarhoven H Front Cell Dev Biol. 2021; 9:743907.

PMID: 34646829 PMC: 8502878. DOI: 10.3389/fcell.2021.743907.

Overexpression of ADAM9 decreases radiosensitivity of hepatocellular carcinoma cell by activating autophagy.

Zhu L, Zhao Y, Yu L, He X, Wang Y, Jiang P Bioengineered. 2021; 12(1):5516-5528.

PMID: 34528498 PMC: 8806855. DOI: 10.1080/21655979.2021.1965694.

The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Binder M, Ward A Int J Mol Sci. 2021; 22(7).

PMID: 33808504 PMC: 8036576. DOI: 10.3390/ijms22073608.

References

Mazzocca A, Coppari R, De Franco R, Cho J, Libermann T, Pinzani M . A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005; 65(11):4728-38. DOI: 10.1158/0008-5472.CAN-04-4449. View

Sung S, Kubo H, Shigemura K, Arnold R, Logani S, Wang R . Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006; 66(19):9519-26. DOI: 10.1158/0008-5472.CAN-05-4375. View

Alfa Cisse M, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F . The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem. 2005; 280(49):40624-31. DOI: 10.1074/jbc.M506069200. View

Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I . ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 2004; 90(5):1053-8. PMC: 2409625. DOI: 10.1038/sj.bjc.6601645. View

OShea C, McKie N, Buggy Y, Duggan C, Hill A, McDermott E . Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003; 105(6):754-61. DOI: 10.1002/ijc.11161. View

Odero-Marah V, Wang R, Chu G, Zayzafoon M, Xu J, Shi C . Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008; 18(8):858-70. DOI: 10.1038/cr.2008.84. View

Nomura T, Huang W, Zhau H, Wu D, Xie Z, Mimata H . Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res. 2006; 12(24):7294-305. DOI: 10.1158/1078-0432.CCR-06-2060. View

Shigemura K, Sung S, Kubo H, Arnold R, Fujisawa M, Gotoh A . Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate. 2007; 67(7):722-31. DOI: 10.1002/pros.20565. View

Zutter M, Sun H, Santoro S . Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia. 2000; 3(2):191-200. DOI: 10.1023/a:1018798907544. View

10.

Franzke C, Tasanen K, Borradori L, Huotari V, Bruckner-Tuderman L . Shedding of collagen XVII/BP180: structural motifs influence cleavage from cell surface. J Biol Chem. 2004; 279(23):24521-9. DOI: 10.1074/jbc.M308835200. View

11.

Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T . Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004; 64(12):4190-6. DOI: 10.1158/0008-5472.CAN-03-3235. View

12.

Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K . A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 1998; 17(24):7260-72. PMC: 1171072. DOI: 10.1093/emboj/17.24.7260. View

13.

Koike H, Tomioka S, Sorimachi H, Saido T, Maruyama K, Okuyama A . Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J. 1999; 343 Pt 2:371-5. PMC: 1220563. View

14.

Fischer O, Hart S, Gschwind A, Prenzel N, Ullrich A . Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol. 2004; 24(12):5172-83. PMC: 419881. DOI: 10.1128/MCB.24.12.5172-5183.2004. View

15.

Fritzsche F, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K . ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2007; 54(5):1097-106. DOI: 10.1016/j.eururo.2007.11.034. View

16.

Edwards D, Handsley M, Pennington C . The ADAM metalloproteinases. Mol Aspects Med. 2008; 29(5):258-89. PMC: 7112278. DOI: 10.1016/j.mam.2008.08.001. View

17.

Peduto L, Reuter V, Shaffer D, Scher H, Blobel C . Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005; 65(20):9312-9. DOI: 10.1158/0008-5472.CAN-05-1063. View

18.

Zhau H, Odero-Marah V, Lue H, Nomura T, Wang R, Chu G . Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis. 2008; 25(6):601-10. PMC: 3050737. DOI: 10.1007/s10585-008-9183-1. View

19.

Mohan S, Thompson G, Amaar Y, Hathaway G, Tschesche H, Baylink D . ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry. 2002; 41(51):15394-403. DOI: 10.1021/bi026458q. View

20.

Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y . Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2005; 312(3):331-9. DOI: 10.1016/j.yexcr.2005.10.032. View